Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Fucosylated glycoproteomic approach to identify a complement component 9 associated with squamous cell lung cancer (SQLC).

Narayanasamy A, Ahn JM, Sung HJ, Kong DH, Ha KS, Lee SY, Cho JY.

J Proteomics. 2011 Nov 18;74(12):2948-58. doi: 10.1016/j.jprot.2011.07.019. Epub 2011 Aug 3.

PMID:
21840429
2.

Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer.

Ahn JM, Sung HJ, Yoon YH, Kim BG, Yang WS, Lee C, Park HM, Kim BJ, Kim BG, Lee SY, An HJ, Cho JY.

Mol Cell Proteomics. 2014 Jan;13(1):30-48. doi: 10.1074/mcp.M113.028621. Epub 2013 Oct 1.

3.

Fucosylation of serum glycoproteins in lung cancer patients.

Kossowska B, Ferens-Sieczkowska M, Gancarz R, Passowicz-Muszyńska E, Jankowska R.

Clin Chem Lab Med. 2005;43(4):361-9.

PMID:
15899650
4.

Differential proteomic approach for identification and verification of aberrantly glycosylated proteins in adenocarcinoma lung cancer (ADLC) plasmas by lectin-capturing and targeted mass spectrometry.

Ahn YH, Ji ES, Oh NR, Kim YS, Ko JH, Yoo JS.

J Proteomics. 2014 Jun 25;106:221-9. doi: 10.1016/j.jprot.2014.04.031. Epub 2014 Apr 26.

PMID:
24780727
5.

Development of an AlphaLISA assay to quantify serum core-fucosylated E-cadherin as a metastatic lung adenocarcinoma biomarker.

Wen CL, Chen KY, Chen CT, Chuang JG, Yang PC, Chow LP.

J Proteomics. 2012 Jul 16;75(13):3963-76. doi: 10.1016/j.jprot.2012.05.015. Epub 2012 May 23.

PMID:
22634079
6.

Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS.

Wu J, Xie X, Liu Y, He J, Benitez R, Buckanovich RJ, Lubman DM.

J Proteome Res. 2012 Sep 7;11(9):4541-52. doi: 10.1021/pr300330z. Epub 2012 Aug 6.

PMID:
22827608
7.

Comparative proteomics, network analysis and post-translational modification identification reveal differential profiles of plasma Con A-bound glycoprotein biomarkers in gastric cancer.

Uen YH, Lin KY, Sun DP, Liao CC, Hsieh MS, Huang YK, Chen YW, Huang PH, Chen WJ, Tai CC, Lee KW, Chen YC, Lin CY.

J Proteomics. 2013 May 27;83:197-213. doi: 10.1016/j.jprot.2013.03.007. Epub 2013 Mar 26.

PMID:
23541716
8.

Increased α1-3 fucosylation of α-1-acid glycoprotein (AGP) in pancreatic cancer.

Balmaña M, Giménez E, Puerta A, Llop E, Figueras J, Fort E, Sanz-Nebot V, de Bolós C, Rizzi A, Barrabés S, de Frutos M, Peracaula R.

J Proteomics. 2016 Jan 30;132:144-54. doi: 10.1016/j.jprot.2015.11.006. Epub 2015 Nov 10.

PMID:
26563517
9.

Squamous cell carcinoma antigen in lung cancer and nonmalignant respiratory diseases.

Kagohashi K, Satoh H, Kurishima K, Kadono K, Ishikawa H, Ohtsuka M, Sekizawa K.

Lung. 2008 Sep-Oct;186(5):323-6. doi: 10.1007/s00408-008-9108-4. Epub 2008 Jul 29.

PMID:
18663529
10.

Glycoproteomics analysis to identify a glycoform on haptoglobin associated with lung cancer.

Tsai HY, Boonyapranai K, Sriyam S, Yu CJ, Wu SW, Khoo KH, Phutrakul S, Chen ST.

Proteomics. 2011 Jun;11(11):2162-70. doi: 10.1002/pmic.201000319. Epub 2011 May 2.

PMID:
21538882
11.

Upregulation of plasma C9 protein in gastric cancer patients.

Chong PK, Lee H, Loh MC, Choong LY, Lin Q, So JB, Lim KH, Soo RA, Yong WP, Chan SP, Smoot DT, Ashktorab H, Yeoh KG, Lim YP.

Proteomics. 2010 Sep;10(18):3210-21. doi: 10.1002/pmic.201000127.

12.

Subunit-specific mass spectrometry method identifies haptoglobin subunit alpha as a diagnostic marker in non-small cell lung cancer.

Park J, Yang JS, Jung G, Woo HI, Park HD, Kim JW, Huh W, Ko JW, Kim H, Cho JY, Lee SY.

J Proteomics. 2013 Dec 6;94:302-10. doi: 10.1016/j.jprot.2013.09.019. Epub 2013 Oct 11.

PMID:
24120528
13.

Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis.

Abbott KL, Lim JM, Wells L, Benigno BB, McDonald JF, Pierce M.

Proteomics. 2010 Feb;10(3):470-81. doi: 10.1002/pmic.200900537.

14.

Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry.

Zeng X, Hood BL, Sun M, Conrads TP, Day RS, Weissfeld JL, Siegfried JM, Bigbee WL.

J Proteome Res. 2010 Dec 3;9(12):6440-9. doi: 10.1021/pr100696n. Epub 2010 Oct 28.

15.

Pathways enrichment analysis for differentially expressed genes in squamous lung cancer.

Qian L, Luo Q, Zhao X, Huang J.

Pathol Oncol Res. 2014 Jan;20(1):197-202. doi: 10.1007/s12253-013-9685-2. Epub 2013 Oct 10.

PMID:
24114512
16.
17.

Elevated levels of abnormally-fucosylated haptoglobins in cancer sera.

Thompson S, Turner GA.

Br J Cancer. 1987 Nov;56(5):605-10.

18.

α1-3/4 fucosylation at Asn 241 of β-haptoglobin is a novel marker for colon cancer: a combinatorial approach for development of glycan biomarkers.

Park SY, Lee SH, Kawasaki N, Itoh S, Kang K, Hee Ryu S, Hashii N, Kim JM, Kim JY, Hoe Kim J.

Int J Cancer. 2012 May 15;130(10):2366-76. doi: 10.1002/ijc.26288. Epub 2011 Sep 22.

19.

Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer.

Liang Y, Ma T, Thakur A, Yu H, Gao L, Shi P, Li X, Ren H, Jia L, Zhang S, Li Z, Chen M.

Glycobiology. 2015 Mar;25(3):331-40. doi: 10.1093/glycob/cwu115. Epub 2014 Oct 27.

20.

Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot.

Qiu Y, Patwa TH, Xu L, Shedden K, Misek DE, Tuck M, Jin G, Ruffin MT, Turgeon DK, Synal S, Bresalier R, Marcon N, Brenner DE, Lubman DM.

J Proteome Res. 2008 Apr;7(4):1693-703. doi: 10.1021/pr700706s. Epub 2008 Feb 27.

Items per page

Supplemental Content

Write to the Help Desk